Physician profile
Ashok P Devatha
NPI 1497740328
$5,782.02
in general payments reported to CMS, 2019-2025
26 companies · $964 in 2025
The $964 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $661 · 2021: $665 · 2022: $834 · 2023: $492 · 2024: $1,104 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,559.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,388.19 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $530.39 | 2019-2024 | Capvaxive |
| Janssen Pharmaceuticals, INC | $346.92 | 2019-2022 | |
| Pfizer INC. | $339.69 | 2019-2025 | |
| Amarin Pharma, INC. | $276.71 | 2019-2022 | |
| Novo Nordisk INC | $271.70 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $262.77 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.15 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $162.47 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $156.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $149.01 | 2022 | |
| Lilly USA, LLC | $136.18 | 2024-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $119.02 | 2022-2024 | Vraylar |
| Madrigal Pharmaceuticals | $88.64 | 2024-2025 | Resmetirom, Rezdiffra |
| Genentech USA, INC. | $72.92 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $39.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $33.07 | 2019 | |
| Biogen, INC. | $30.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.28 | 2019 | |
| Currax Pharmaceuticals LLC | $23.97 | 2020 | |
| Eisai INC. | $20.58 | 2025 | |
| Boston Scientific Corporation | $20.30 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $19.96 | 2025 | |
| Abbott Laboratories | $12.42 | 2022 | |
| Zealand Pharma US, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Devatha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.